These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 8100643)

  • 1. Tardive dyskinesia.
    Jeste DV; Caligiuri MP
    Schizophr Bull; 1993; 19(2):303-15. PubMed ID: 8100643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The current prevalence and factors associated with tardive dyskinesia among Filipino schizophrenic patients.
    Go CL; Rosales RL; Caraos RJ; Fernandez HH
    Parkinsonism Relat Disord; 2009 Nov; 15(9):655-9. PubMed ID: 19346155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
    Morgenstern H; Glazer WM
    Arch Gen Psychiatry; 1993 Sep; 50(9):723-33. PubMed ID: 8102845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis.
    Apud JA; Egan MF; Wyatt RJ
    Schizophr Res; 2003 Sep; 63(1-2):151-60. PubMed ID: 12892869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tardive dyskinesia: prevalence, incidence, and risk factors.
    Kane JM; Woerner M; Lieberman J
    Psychopharmacology Suppl; 1985; 2():72-8. PubMed ID: 2860662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study.
    Gharabawi GM; Bossie CA; Zhu Y; Mao L; Lasser RA
    Schizophr Res; 2005 Sep; 77(2-3):129-39. PubMed ID: 15913962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.
    Chakos MH; Alvir JM; Woerner MG; Koreen A; Geisler S; Mayerhoff D; Sobel S; Kane JM; Borenstein M; Lieberman JA
    Arch Gen Psychiatry; 1996 Apr; 53(4):313-9. PubMed ID: 8634009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The current status of tardive dyskinesia.
    Sachdev PS
    Aust N Z J Psychiatry; 2000 Jun; 34(3):355-69. PubMed ID: 10881961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tardive dyskinesia and diabetes mellitus.
    Ganzini L; Casey DE; Hoffman WF; Heintz RT
    Psychopharmacol Bull; 1992; 28(3):281-6. PubMed ID: 1362276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients.
    Ghadirian AM; Annable L; Bélanger MC; Chouinard G
    J Clin Psychiatry; 1996 Jan; 57(1):22-8. PubMed ID: 8543543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dogma disputed: is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivity?
    Jeste DV; Wyatt RJ
    J Clin Psychiatry; 1981 Dec; 42(12):455-7. PubMed ID: 6118358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia.
    Achalia RM; Chaturvedi SK; Desai G; Rao GN; Prakash O
    Asian J Psychiatr; 2014 Jun; 9():31-5. PubMed ID: 24813033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.
    Jeste DV; Caligiuri MP; Paulsen JS; Heaton RK; Lacro JP; Harris MJ; Bailey A; Fell RL; McAdams LA
    Arch Gen Psychiatry; 1995 Sep; 52(9):756-65. PubMed ID: 7654127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A summary of current knowledge of tardive dyskinesia.
    Baldessarini RJ
    Encephale; 1988 Sep; 14 Spec No():263-8. PubMed ID: 2905654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tardive dyskinesia outcomes: clinical and pharmacologic correlates of remission and persistence.
    Cavallaro R; Regazzetti MG; Mundo E; Brancato V; Smeraldi E
    Neuropsychopharmacology; 1993 May; 8(3):233-9. PubMed ID: 8099483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A prospective study of tardive dyskinesia in Japan.
    Inada T; Ohnishi K; Kamisada M; Matsuda G; Tajima O; Yanagisawa Y; Hashiguchi K; Shima S; Oh-e Y; Masuda Y
    Eur Arch Psychiatry Clin Neurosci; 1991; 240(4-5):250-4. PubMed ID: 1675874
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study.
    Ganzini L; Heintz RT; Hoffman WF; Casey DE
    Arch Gen Psychiatry; 1991 Mar; 48(3):259-63. PubMed ID: 1671743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevalence of and risk factors for respiratory dyskinesia.
    Hayashi T; Nishikawa T; Koga I; Uchida Y; Yamawaki S
    Clin Neuropharmacol; 1996 Oct; 19(5):390-8. PubMed ID: 8889282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study.
    Sachdev P
    Aust N Z J Psychiatry; 2004 Jun; 38(6):445-9. PubMed ID: 15209837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.